Total
0
Shares
Creso Pharma (ASX:CPH) - Creso Pharma
Creso Pharma
Source: Creso Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Creso Pharma (CPH) launches new ecommerce channels and expands into Poland with a maiden purchase order secured
  • These ecommerce channels will host a range of Creso Pharma’s products which are designed for the human health, sports and wellness sectors
  • Creso Pharma has also entered into the Polish animal health market following a CHF54120 (A$80,141) purchase order from Polvet
  • This purchase is for Creso Pharma’s hemp flour-based anibidiol granule product for pets and livestock to support stress management before surgery
  • Creso Pharma closed flat on the market with shares trading at 12 cents apiece

Creso Pharma (CPH) has launched new e-commerce channels and expanded into Poland with a maiden purchase order secured.

Ecommerce channels

The ecommerce channels are now operational and will host a range of Creso Pharma’s new human health products which are designed for the health, sports and wellness sectors.

It includes the company’s cannaDOL range which will be named under the new brand, Born to move.

The Born to move products include cannaDOL booster for use before sport and recreational activities, cannaDOL revitalise gel for soothing and relaxing effects, and cannaDOL recovery to help in the recovery from sport and physical activities.

These products are based on Creso Pharma’s recently developed and innovative hemp CBD tea-based technology.

Creso Pharma will initially target Swiss customers as Switzerland has annual per capita expenditure of CHF2500 (A$3692.80) in its CHF21 billion (A$31 billion) sports related activities market.

Creso Pharma’s ‘Born to move’ range

Creso Pharma is confident that these products will pave way to a range of new consumers and help the company expand its Swiss footprint.

Head of International Operations Director Jorge Wernli commented on the products.

“Following the launch of our new ecommerce platform with the revitalised cannaDOL product range, we can now directly target consumers and unlock another potential revenue stream and addressable market,” Mr Wernli said.

“We will continue to pursue growth opportunities across Europe and can now focus on both business to business and direct to consumer paths.”

Poland expansion

Creso Pharma has also entered into the Polish animal health market following a CHF54120 (A$80,141) purchase order from Polvet.

This purchase is for Creso Pharma’s hemp flour-based anibidiol granule product for pets, livestock and large companion animals.

This granule is designed for use on pets and livestock before and after surgery as it supports stress management and improves wellbeing.

Polvet is a medical and pharmaceutical company that provides both animal and human services across the country. It has three animal clinics across Australia.

Polvet CEO Oliwier Theodorowski commented on the partnership.

“At Polvet, we are keen on working with companies developing, producing and marketing innovative products such as hemp flour based anibidiol,” Dr Theodorowski said.

“Anibidiol is unique and we are looking forward to building up this success with Creso Pharma.”

Creso Pharma closed flat on the market with shares trading at 12 cents apiece.

CPH by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.